Internal Medicine, Rheumatology · Grand Rapids, MI
NPI
1417478660
Since 2017
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
3271 Clear Vista Ct NE
Grand Rapids, MI, 49525
Phone (616) 267-7293
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.6M
170,186 services
Medicare patients, 2024
718
Average age 74
Drug cost, 2024
$2.8M
4,072 prescriptions
Company payments, 2025
$361
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Zhe Liang was code J3262 (injection, tocilizumab, 1 mg), 98,201 times for 32 patients. In total Zhe Liang billed 170,186 services in 68 codes, and Medicare paid $1.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 98,201 | 32 | $4.69 | $461K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 20,850 | 36 | $8.93 | $186K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 9,625 | 39 | $33.34 | $321K |
| J0897 Injection, denosumab, 1 mg | Office | 8,880 | 111 | $20.12 | $179K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 7,770 | 13 | $8.55 | $66K |
| J7329 Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg | Office | 6,525 | 46 | $5.65 | $37K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 6,270 | 32 | $24.52 | $154K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 1,199 | 152 | $0.74 | $890 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 875 | 13 | $0.22 | $192 |
| 99214 Office E&M - Established | Office | 665 | 398 | $85.28 | $57K |
| 20611 Joint Injection | Office | 322 | 110 | $83.88 | $27K |
| 96413 Chemotherapy Administration | Office | 294 | 78 | $90.56 | $27K |
| 96365 Intravenous Infusion, Hydration | Office | 276 | 108 | $44.90 | $12K |
| 96372 Injection Administration | Office | 272 | 139 | $10.68 | $2,905 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 215 | 43 | $4.51 | $971 |
By year: 2022 $290K for 22,065 services; 2023 $1.1M for 96,545 services; 2024 $1.6M for 170,186 services.
Medicare prescription drug claims, 2024
In 2024, the drug Zhe Liang prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 497 prescriptions and refills. In total Zhe Liang wrote 4,072 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 497 | 1,191 | 154 | $14K |
| Prednisone Generic | 447 | 837 | 172 | $2,984 |
| Hydroxychloroquine Sulfate Generic | 330 | 793 | 100 | $8,638 |
| Gabapentin Generic | 242 | 576 | 76 | $3,882 |
| Sulfasalazine Dr Sulfasalazine | 233 | 449 | 70 | $11K |
| Leflunomide Generic | 190 | 476 | 63 | $8,068 |
| Meloxicam Generic | 144 | 297 | 46 | $516 |
| Allopurinol Generic | 143 | 363 | 38 | $899 |
| Alendronate Sodium Generic | 130 | 296 | 43 | $961 |
| Methylprednisolone Generic | 119 | 119 | 95 | $515 |
| Celecoxib Generic | 109 | 247 | 34 | $2,925 |
| Duloxetine Hcl Generic | 108 | 271 | 35 | $1,632 |
| Humira(Cf) Pen Adalimumab | 99 | 99 | 15 | $674K |
| Pregabalin Generic | 79 | 131 | 29 | $2,838 |
| Cyclobenzaprine Hcl Generic | 78 | 146 | 31 | $748 |
Brand drugs: 729 claims; generic drugs: 3,318 claims; opioid claims: 110.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Zhe Liang $361 ($361 in general payments such as food, travel and fees) from 5 companies. The largest payer was Amgen Inc. with $211.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.